Tag Archives: GLP-1 therapy

The choice between oral GLP-1 and injectable therapy is quickly becoming a central question in type 2 diabetes care. With the arrival of oral semaglutide, clinicians now have more flexibility than ever. But how do you decide between a daily pill and a weekly injection? While both options target the …

Care fragmentation in GLP-1 therapy is becoming a growing concern as more patients receive prescriptions from multiple providers. As GLP-1 receptor agonists gain popularity for diabetes and weight management, care often spans endocrinologists, primary care physicians, telehealth platforms, and retail clinics. But what happens when these providers are not aligned? …

As GLP-1 receptor agonists become a cornerstone of diabetes care, clinicians are rethinking how often patients on GLP-1 therapy need follow-up visits. These therapies often deliver improved glycemic control, weight loss, and cardiovascular benefits. However, does this stability mean fewer clinic visits, or does it require closer monitoring in new …

A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …

Prioritizing diabetes visits has become essential as clinical care grows more complex and time-limited. With new medications, tighter guidelines, and multiple comorbidities, clinicians often feel like they are solving a puzzle against the clock. So how can you make every minute count without sacrificing care quality? This guide breaks down …

Telehealth prescribing of GLP-1 medications is rapidly reshaping how diabetes and weight management care is delivered. But as access expands, an important question emerges: who is truly managing patient care? Like a relay race without a clear handoff, patients often move between providers, platforms, and pharmacies without consistent oversight. As …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

Why do some patients experience dramatic weight loss on GLP-1 therapies while others barely see a change? This question highlights growing interest in how patients respond differently to GLP-1 therapies, challenging the idea of “average” outcomes seen in clinical trials. While studies often report impressive results, real-world experiences show a …

GLP-1 dose escalation is quickly becoming a central topic in diabetes care, especially as higher dosing strategies gain traction. But are we truly entering a high-dose era, or simply refining how we use these powerful agents? As clinicians face patients who plateau on standard regimens, the question becomes not just …